PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.
You may also be interested in...
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.
FDA panelists' confusion over biosimilarity and overwhelming approval endorsements following glowing agency reviews suggest the meetings may not be having much impact on FDA deliberations; however, agency sees an opportunity to learn from what its external experts don't understand about biosimilars.
Industry and FDA are in the process of ratifying the commitment letter for BsUFA II, leaving only the generic drug user fee program still ongoing.